Adherence to sacubitril/valsartan was relatively good, at about 86% of prescribed patients with HF, but adherence behaviors were found to vary across subgroups, according to data published in the ...

Heart failure patients unable to reach the target dose of angiotensin receptor/neprilysin inhibitor (ARNI) therapy still reaped gains in health status a year later, according to a post hoc analysis of ...

Sacubitril, valsartan; 6mg/6mg, 15mg/16mg; oral pellets in caps. Entresto Sprinkle is supplied as film-coated oral pellets are round, biconvex in shape, and provided in a hard capsule in the following ...

A common heart medication may contain a cancer-causing chemical, the FDA said. The U.S. Food and Drug Administration (FDA) is expanding a recall of a common heart medication because it may contain a ...

Recent study findings highlight mixed results following use of this medication among Mississippi and Massachusetts Medicaid beneficiaries. Results from 2 investigations highlight the mixed ...

The US Food and Drug Administration (FDA) has approved sacubitril/valsartan (Entresto, Novartis) for the treatment of symptomatic heart failure (HF) with systemic left ventricular systolic dysfunction ...

The US Food and Drug Administration (FDA) has approved a groundbreaking expanded indication for sacubitril/valsartan (Entresto), making it the first drug in the United States indicated for chronic ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...